Highlights of the NCCN Oncology Research Program

CV CARE is a trial enrolling patients undergoing treatment with androgen deprivation therapy (ADT) in order to assess and manage reversible cardiovascular (CV) risk factors.In this quality improvement initiative within the Dana-Farber Cancer Institute (DFCI) genitourinary oncology clinic, the clinical team will systematically leverage existing follow-up visits for prostate cancer care by integrating CV risk assessment, electronic medical record alerts and communications, and counseling to ensure improved adherence to guideline recommendations addressing reversible CV risk factors.The initiative also includes standardized communications with local cardiology care or seamless referral to cardio-oncology for the highest-risk patients who do not have known cardiac care providers.This research is being conducted to test a program to assess and manage reversible CV risk factors in participants with prostate cancer starting ADT, with the goal of integrating a standardized method into DFCI clinics for all such patients.After completing an initial iteration, the study will gather feedback from clinician and patient participants to identify areas for improvement.These changes will be made when feasible, and a second program, CV CARE 2, will be launched based on the learnings from the primary initiative.